Fascial nerve block for cardiac surgery using a robot

Erector Spinae Plane block in robotic cardiac surgery

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2021-000574-29-ES

Enrollment

Registered

2021-06-11

Start date

2021-09-22

Completion date

Unknown

Last updated

2021-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative pain

Interventions

Trade Name: Ropivacaine Inibsa Product Name: Ropivacaine Product Code: Ropivacaine Pharmaceutical Form: INN or Proposed INN: ROPIVACAINE CAS Number: 84057-95-4 Other descriptive name: ROPIVACAINE HYD

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients > 18yo undergoing robotic mitral valve repair Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 22 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 22

Exclusion criteria

Exclusion criteria: Allergy to any medication used in the study, chronic pain, background of psychiatric disease or substance abuse

Design outcomes

Primary

Measure	Time frame
Main Objective: To assess the analgesic efficacy of the ESP block during the first 48h after robotic cardiac surgery;Secondary Objective: Quantify postoperative pain, record complications;Primary end point(s): Differences on morphine consumption;Timepoint(s) of evaluation of this end point: 12,24 and 48 hours	—

Secondary

Measure	Time frame
Secondary end point(s): Pain intensity measured by numeric verbal scale;Timepoint(s) of evaluation of this end point: 12, 24 y 48 horas	—

Countries

Spain

Contacts

Public ContactRosa Vilavella

Fundació Clinic

fclinic@clinic.ub.es+34932275707

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026